597 related articles for article (PubMed ID: 17875725)
1. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane.
Lyu YL; Kerrigan JE; Lin CP; Azarova AM; Tsai YC; Ban Y; Liu LF
Cancer Res; 2007 Sep; 67(18):8839-46. PubMed ID: 17875725
[TBL] [Abstract][Full Text] [Related]
2. The Role of Topoisomerase IIβ in the Mechanisms of Action of the Doxorubicin Cardioprotective Agent Dexrazoxane.
Hasinoff BB; Patel D; Wu X
Cardiovasc Toxicol; 2020 Jun; 20(3):312-320. PubMed ID: 31773441
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
[TBL] [Abstract][Full Text] [Related]
4. Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms.
Deng S; Yan T; Jendrny C; Nemecek A; Vincetic M; Gödtel-Armbrust U; Wojnowski L
BMC Cancer; 2014 Nov; 14():842. PubMed ID: 25406834
[TBL] [Abstract][Full Text] [Related]
5. Regulation of topoisomerase II stability and activity by ubiquitination and SUMOylation: clinical implications for cancer chemotherapy.
Ma Y; North BJ; Shu J
Mol Biol Rep; 2021 Sep; 48(9):6589-6601. PubMed ID: 34476738
[TBL] [Abstract][Full Text] [Related]
6. Genistein induces topoisomerase IIbeta- and proteasome-mediated DNA sequence rearrangements: Implications in infant leukemia.
Azarova AM; Lin RK; Tsai YC; Liu LF; Lin CP; Lyu YL
Biochem Biophys Res Commun; 2010 Aug; 399(1):66-71. PubMed ID: 20638367
[TBL] [Abstract][Full Text] [Related]
7. A QSAR study that compares the ability of bisdioxopiperazine analogs of the doxorubicin cardioprotective agent dexrazoxane (ICRF-187) to protect myocytes with DNA topoisomerase II inhibition.
Hasinoff BB; Patel D; Wu X
Toxicol Appl Pharmacol; 2020 Jul; 399():115038. PubMed ID: 32417440
[TBL] [Abstract][Full Text] [Related]
8. The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells.
Deng S; Yan T; Nikolova T; Fuhrmann D; Nemecek A; Gödtel-Armbrust U; Kaina B; Wojnowski L
Br J Pharmacol; 2015 May; 172(9):2246-57. PubMed ID: 25521189
[TBL] [Abstract][Full Text] [Related]
9. Molecular Mechanisms of the Cardiotoxicity of the Proteasomal-Targeted Drugs Bortezomib and Carfilzomib.
Hasinoff BB; Patel D; Wu X
Cardiovasc Toxicol; 2017 Jul; 17(3):237-250. PubMed ID: 27388042
[TBL] [Abstract][Full Text] [Related]
10. Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase II
Kollárová-Brázdová P; Jirkovská A; Karabanovich G; Pokorná Z; Bavlovič Piskáčková H; Jirkovský E; Kubeš J; Lenčová-Popelová O; Mazurová Y; Adamcová M; Skalická V; Štěrbová-Kovaříková P; Roh J; Šimůnek T; Štěrba M
J Pharmacol Exp Ther; 2020 Jun; 373(3):402-415. PubMed ID: 32253261
[TBL] [Abstract][Full Text] [Related]
11. Role of hypoxia-inducible factors in the dexrazoxane-mediated protection of cardiomyocytes from doxorubicin-induced toxicity.
Spagnuolo RD; Recalcati S; Tacchini L; Cairo G
Br J Pharmacol; 2011 May; 163(2):299-312. PubMed ID: 21232037
[TBL] [Abstract][Full Text] [Related]
12. Topoisomerase 2β: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity.
Vejpongsa P; Yeh ET
Clin Pharmacol Ther; 2014 Jan; 95(1):45-52. PubMed ID: 24091715
[TBL] [Abstract][Full Text] [Related]
13. Exploring the effects of topoisomerase II inhibitor XK469 on anthracycline cardiotoxicity and DNA damage.
Keresteš V; Kubeš J; Applová L; Kollárová P; Lenčová-Popelová O; Melnikova I; Karabanovich G; Khazeem MM; Bavlovič-Piskáčková H; Štěrbová-Kovaříková P; Austin CA; Roh J; Štěrba M; Šimůnek T; Jirkovská A
Toxicol Sci; 2024 Mar; 198(2):288-302. PubMed ID: 38290791
[TBL] [Abstract][Full Text] [Related]
14. Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells.
Vavrova A; Jansova H; Mackova E; Machacek M; Haskova P; Tichotova L; Sterba M; Simunek T
PLoS One; 2013; 8(10):e76676. PubMed ID: 24116135
[TBL] [Abstract][Full Text] [Related]
15. The topoisomerase IIbeta circular clamp arrests transcription and signals a 26S proteasome pathway.
Xiao H; Mao Y; Desai SD; Zhou N; Ting CY; Hwang J; Liu LF
Proc Natl Acad Sci U S A; 2003 Mar; 100(6):3239-44. PubMed ID: 12629207
[TBL] [Abstract][Full Text] [Related]
16. A protease pathway for the repair of topoisomerase II-DNA covalent complexes.
Zhang A; Lyu YL; Lin CP; Zhou N; Azarova AM; Wood LM; Liu LF
J Biol Chem; 2006 Nov; 281(47):35997-6003. PubMed ID: 16973621
[TBL] [Abstract][Full Text] [Related]
17. The cardioprotective and DNA topoisomerase II inhibitory agent dexrazoxane (ICRF-187) antagonizes camptothecin-mediated growth inhibition of Chinese hamster ovary cells by inhibition of DNA synthesis.
Hasinoff BB; Chee GL; Thampatty P; Allan WP; Yalowich JC
Anticancer Drugs; 1999 Jan; 10(1):47-54. PubMed ID: 10194547
[TBL] [Abstract][Full Text] [Related]
18. Topoisomerase IIβ deficiency enhances camptothecin-induced apoptosis.
Lin RK; Ho CW; Liu LF; Lyu YL
J Biol Chem; 2013 Mar; 288(10):7182-92. PubMed ID: 23344961
[TBL] [Abstract][Full Text] [Related]
19. Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIβ inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity.
Bavlovič Piskáčková H; Jansová H; Kubeš J; Karabanovich G; Váňová N; Kollárová-Brázdová P; Melnikova I; Jirkovská A; Lenčová-Popelová O; Chládek J; Roh J; Šimůnek T; Štěrba M; Štěrbová-Kovaříková P
Sci Rep; 2021 Feb; 11(1):4456. PubMed ID: 33627707
[TBL] [Abstract][Full Text] [Related]
20. Topoisomerase II{alpha}-dependent and -independent apoptotic effects of dexrazoxane and doxorubicin.
Yan T; Deng S; Metzger A; Gödtel-Armbrust U; Porter AC; Wojnowski L
Mol Cancer Ther; 2009 May; 8(5):1075-85. PubMed ID: 19417146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
